XML 33 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition
 12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenue recognition REVENUE RECOGNITION Revenue is recognized when or as a customer obtains control of promised products. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products.
Disaggregation of Revenue

We generated net sales in the following geographic locations(1) during each of the periods presented below (in millions):
Year Ended
December 31,
2021		December 31,
2020		December 31,
2019
U.S.$2,565.9 $2,579.0 $2,360.3 
Europe(2)
1,393.0 1,350.6 1,335.8 
All other countries(3)
179.8 158.6 173.8 
Total net sales$4,138.7 $4,088.2 $3,869.9 

(1)    The net sales by geography is derived from the location of the entity that sells to a third party.
(2)    Includes Ireland net sales of $23.7 million, $29.8 million, and $23.4 million for the years ended December 31, 2021, December 31, 2020, and December 31, 2019, respectively.
(3)    Includes revenue generated primarily in Mexico, Australia, and Canada.
    
Product Category

The following is a summary of our net sales by category (in millions):

Year Ended
December 31, 2021December 31, 2020December 31,
2019
CSCA(1)
Upper respiratory$483.1 $505.8 $529.3 
Digestive health475.1 471.3 429.2 
Pain and sleep-aids405.4 434.5 390.9 
Nutrition401.9 388.3 395.3 
Oral care311.9 288.2 111.7 
Healthy lifestyle297.7 352.4 356.1 
Skincare and personal hygiene219.2 200.6 191.3 
Vitamins, minerals, and supplements31.7 27.0 28.6 
Animal health— — 43.7 
Other CSCA(2)
67.1 24.9 11.6 
Total CSCA2,693.1 2,693.0 2,487.7 
CSCI
Skincare and personal hygiene394.3 351.8 371.6 
Upper respiratory226.2 255.1 276.8 
Vitamins, minerals, and supplements217.4 201.0 180.2 
Pain and sleep-aids201.8 190.4 167.9 
Healthy lifestyle179.3 165.4 173.8 
Oral care95.8 97.8 51.2 
Digestive health38.4 26.5 27.1 
Other CSCI(3)
92.4 107.2 133.6 
Total CSCI1,445.6 1,395.2 1,382.2 
Total net sales$4,138.7 $4,088.2 $3,869.9 

(1)    Includes net sales from our OTC contract manufacturing business.
(2)    Consists primarily of product sales and royalty income related to supply and distribution agreements, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
(3)    Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $299.7 million, $261.4 million, and $285.3 million for the years ended December 31, 2021, December 31, 2020, and December 31, 2019, respectively.

We also recognize a portion of the store brand OTC product revenues in the CSCA segment on an over time basis; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery.

Contract Balances

The following table provides information about contract assets from contracts with customers (in millions):
Balance Sheet LocationDecember 31,
2021		December 31,
2020
Short-term contract assetsPrepaid expenses and other current assets$40.2 $19.7